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ABSTRACT
Background and Objectives: The aging population is rapidly increasing, and atrial 
fibrillation (AF) is becoming a significant public health burden in Asia, including Korea. This 
study evaluated current treatment patterns and guideline adherence of AF treatment.
Methods: In a prospective observational registry (COmparison study of Drugs for symptom 
control and complication prEvention of Atrial Fibrillation [CODE-AF] registry), 6,275 
patients with nonvalvular AF were consecutively enrolled between June 2016 and April 2017 
from 10 tertiary hospitals in Korea.
Results: The AF type was paroxysmal, persistent, and permanent in 65.3%, 30.0%, and 2.9% 
of patients, respectively. Underlying structural heart disease was present in 11.9%. Mean 
CHA2DS2-VASc was 2.7±1.7. Oral anticoagulation (OAC), rate control, and rhythm control 
were used in 70.1%, 53.9%, and 54.4% of patients, respectively. OAC was performed in 82.7% 
of patients with a high stroke risk. However, antithrombotic therapy was inadequately used 
in 53.4% of patients with a low stroke risk. For rate control in 192 patients with low ejection 
fraction (<40%), β-blocker (65.6%), digoxin (5.2%), or both (19.3%) were adequately used 
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in 90.1% of patients; however, a calcium channel blocker was inadequately used in 9.9%. 
A rhythm control strategy was chosen in 54.4% of patients. The prescribing rate of class Ic 
antiarrythmics, dronedarone, and sotalol was 16.9% of patients with low ejection fraction.
Conclusion: This study shows how successfully guidelines can be applied in the real world. 
The nonadherence rate was 17.2%, 9.9%, and 22.4% for stroke prevention, rate control, and 
rhythm control, respectively.
Keywords: Atrial fibrillation; Anticoagulant agent; Guidelines adherence; Registry
INTRODUCTION
Atrial fibrillation (AF) is the most common, sustained cardiac arrhythmia, occurring in 1–2% 
of the general population,1) and is associated with increased morbidity and mortality.2)3) 
Because AF increases with advancing age, it is becoming a significant public health burden 
in Asia, including Korea, as the aging population rapidly increases. There are 3 therapeutic 
approaches in the treatment of AF: stroke prevention, rate control, and rhythm control.
AF is associated with a 5-fold increase in stroke risk, and 1 in 5 cases of stroke is attributed 
to this arrhythmia.4) Oral anticoagulation (OAC) treatment can prevent ischemic stroke in 
most patients with AF and prolong their lives.5) It is superior to no treatment or aspirin in 
patients with different stroke risk profiles.6) The net clinical benefit is almost universal, with 
the exception of patients with a very low stroke risk; therefore, OAC should be used in most 
patients with AF. Despite this evidence, underuse or premature termination of OAC therapy 
is still common. The effort required to monitor and adjust the dose of vitamin K antagonist 
(VKA) therapy is one of the most common reasons for withholding or ending OAC.7) 
However, the considerable stroke risk without OAC often exceeds the bleeding risk with OAC, 
even in the elderly, patients with cognitive dysfunction, and patients with frequent falls or 
frailty.8) Recently, non-VKA OAC (NOAC) was approved in Korea for stroke prevention in 
patients with AF. However, little contemporary data is currently available on temporal trends 
in anticoagulation therapy in Korea.
Rate control is an integral part of the AF management and is often sufficient to improve AF-
related symptoms. Compared with stroke prevention and rhythm control, very little robust 
evidence exists to identify the best type and intensity of rate control treatment, with most data 
being derived from short-term crossover trials and observational studies.9)10) Pharmacological 
rate control can be achieved for acute or long-term rate control with β-blockers, digoxin, 
calcium channel blockers (CCBs), or combination therapy. Restoring and maintaining 
sinus rhythm is also an integral part of AF management. Antiarrhythmic drugs (AADs) 
approximately double the rate of sinus rhythm compared with placebo.11) Catheter ablation or 
combination therapy is often effective when AADs fail.12)13) Currently, rhythm control therapy 
is indicated to improve symptoms in patients with AF who remain symptomatic despite 
adequate rate control.
Recent advances in the management of AF include treatment strategies (rate vs. rhythm 
control), stroke prevention scales (validation of a new stroke risk index, the CHA2DS2-VASc 
score — congestive heart failure [HF]/left ventricular [LV] dysfunction, hypertension, age 
≥75 years [doubled], diabetes, stroke [doubled], vascular disease, age 65–74 years, and 
sex category [female]), and publication of new guidelines for AF management.14)15) We 
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hypothesized that adherence to anticoagulation guidelines will improve after the introduction 
of NOACs for the treatment of Korean AF patients. We also hypothesized that the usage of rate 
control medication will decrease after the introduction of loose rate control guidelines. The 
objectives of this study were to examine the patterns of treatment and the rates of adherence 
to guidelines for AF treatment, including antithrombotic, rate control, and rhythm control 
therapies in Korea, and to identify predictive factors for appropriate treatment.
METHODS
Study design and centers
The COmparison study of Drugs for symptom control and complication prEvention of 
Atrial Fibrillation (CODE-AF) is a prospective, multicenter, observational study performed 
in patients >18 years with AF at any of 10 tertiary centers, encompassing all geographical 
regions of Korea. The study enrollment period started in June 2016 and will end in October 
2018. The primary objective of the CODE-AF registry is to generate a prospective, multicenter 
AF registry to evaluate the outcomes of medical treatment such as anticoagulation, rate 
control, and rhythm control treatments. The secondary object of the study was to describe 
the clinical epidemiology of patients with AF and to determine the diagnostic and therapeutic 
processes (including the organization of programs for AF management) applied in these 
patients and the clinical outcomes. The registry was designed and coordinated by the Korea 
Heart Rhythm Society, which provides support to related committees, national coordinators, 
and participating centers. Data are entered in a common electronic database that limits 
inconsistencies and errors and provides online help for key variables. Each center has access 
to its own data and data from all other participating centers. The number of patients enrolled 
from each center is shown in Supplementary Figure 1. The study was approved by the ethics 
committee of each center, and all patients provided informed consent for inclusion. This 
study was registered at ClinicalTrials.gov (NCT02786095).
Patients
This study included 6,275 consecutive patients enrolled from June 2016 to April 2017. Each 
center enrolled patients who were >18 years with nonvalvular AF, attended the outpatient 
clinic, and were hospitalized on the same day for AF. Data collection was performed 
according to the same criteria and was usually carried out by personnel with no clinical 
activity assigned to the project. The CHA2DS2-VASc and hypertension, abnormal renal/liver 
function, stroke, bleeding history or predisposition, labile international normalized ratio 
(INR), elderly, concomitant drugs/alcohol (HAS-BLED) scores were calculated for all patients 
with nonvalvular AF.
A follow-up visit was scheduled every 6 months, either through personal interview or 
telephone contact (data not presented).
Definition of guideline adherence
In this population, the most robust recommendations are the 2016 European Society of 
Cardiology and 2014 American Heart Association/American College of Cardiology/Heart 
Rhythm Society guidelines for patients with AF.14)15) Both guidelines recommend estimating 
the stroke risk in patients with AF based on the CHA2DS2-VASc score.14)15) In general, patients 
without clinical stroke risk factors or low risk (CHA2DS2-VASc 0 or 1 [female]) do not need 
antithrombotic therapy, whereas patients with high stroke risk (i.e., CHA2DS2-VASc ≥2) 
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should be treated with OAC.14)15) However, because the recommendations of the 2 guidelines 
were inconsistent in patients with intermediate stroke risk or a CHA2DS2-VASc score of 1 
(male), guideline adherence was not evaluated in these patients.16) Patients with hypertrophic 
cardiomyopathy (HCMP) were excluded from this study.
Beta-blockers and/or digoxin are recommended for rate control in patients with AF with left 
ventricular ejection fraction (LVEF) <40%. Beta-blockers, digoxin, diltiazem, or verapamil are 
recommended for rate control in patients with AF with LVEF ≥40%.14)16)
For rhythm control of AF, dronedarone, flecainide, propafenone, or sotalol are recommended 
for preventing recurrent symptomatic AF in patients with normal LV function and without 
pathological left ventricular hypertrophy (LVH). Dronedarone, sotalol, or amiodarone are 
recommended for preventing recurrent symptomatic AF in patients with stable coronary 
artery disease (CAD) without HF. Amiodarone is recommended for preventing recurrent 
symptomatic AF in patients with HF. Catheter ablation can be used in all patients.14)16)
Finally, in patients with CHA2DS2-VASc score ≤1, anticoagulation can be used due to 
cardioversion, radiofrequency ablation (RFCA), and underlying HCMP. Second, for rhythm 
control in patients with no structural heart disease, amiodarone is recommended as the 
second line agent. However, in the above situations, we could not tell which patients were 
non-adherent to the guideline.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation, and categorical variables 
are reported as frequency (percentage). Statistical analyses were performed with SPSS 21.0 
statistical software (SPSS Inc., Chicago, IL, USA). All p values were 2-tailed, and values 
<0.050 were considered statistically significant.
RESULTS
Baseline characteristics
The patient characteristics are summarized in Table 1. The mean patient age was 67.4±10.8 
years (median, 66.0 years; range, 10–100 years). Male patients were more predominant 
(n=3,966, 63.2%). The type of AF was paroxysmal, persistent, and permanent in 65.3%, 
30.0%, and 2.9% of patients, respectively. Underlying structural heart disease presented 
in 11.9%, including CAD (2.2%) and HF (10.1%). The mean CHA2DS2-VASc and HAS-BLED 
scores were 2.7±1.7 and 1.9±1.1, respectively.
Transechocardiography data were obtained in 5,253 (82.4%) and 873 (13.9%) patients (Table 2). 
The mean LV ejection was 61.1±11.8, and the mean left atrial diameter was 43.8±10.4 mm.
Pattern of and adherence to anticoagulation therapy
OAC was performed in 4,399 (70.1%) patients, with NOACs and warfarin in used 3,081 
(49.1%) and 1,318 (21.0%) patients, respectively.
Figure 1 shows the pattern of stroke prevention in AF according to stroke risk. No 
antithrombotic medication was prescribed in 46.6% of 757 patients with a low stroke 
risk. However, OAC and aspirin were inadequately used in 28.3% and 25.1% of patients, 
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respectively. In 863 patients with intermediate risk, OAC was prescribed in 40.8% of patients, 
and aspirin was prescribed in 30.5%. No antithrombotic medication was used in 28.7% of 
patients. In 4,631 patients with a high stroke risk (CHA2DS2-VASc score ≥2), anticoagulation 
was used in 3,832 (82.7%). NOACs and warfarin were used in 61.4% and 21.3% of patients, 
respectively, and were used simultaneously with aspirin in 3.1% of patients. However, only 
aspirin or no medication was used in 8.0% and 9.2% of patients, respectively. Overall, 1,203 
patients (19.2%), including 799 (12.7%) undertreated patients with high stroke risk and 
404 (6.4%) overtreated patients with low stroke risk, received treatment that did not adhere 
to the guidelines. Among 1,011 (76.7%) out of 1,318 patients taking warfarin, the INR was 
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Table 1. Baseline characteristics of patients
Characteristics Value
Total 6,275
Men (No.) 3,966 (63.2)
Age (years) 67.4±10.8
BMI (kg/m2) 24.6±3.3
Type of AF
Paroxysmal 4,100 (65.3)
Persistent 1,883 (30)
Permanent 182 (2.9)
Unknown 110 (1.7)
CHA2DS2-VASc score 2.7±1.7
HAS-BLED score 1.9±1.1
Valve disease 643 (10.3)
HF 632 (10.1)
Hypertension 4,240 (67.6)
Diabetes mellitus 1,597 (25.5)
History of stroke/TIA 952 (15.2)
History of MI/PAD 533 (8.5)
Cancer 630 (10)
CKD 621 (9.9)
ESRD 101 (1.6)
History of bleeding 582 (9.3)
Treatment
NOAC or warfarin 4,399 (70.1)
Rate control 3,383 (53.9)
Rhythm control 3,414 (54.4)
Data are presented as mean±standard deviation or number (percentage).
AF = atrial fibrillation; BMI = body mass index; CKD = chronic kidney disease; ESRD = end-stage renal disease; HAS-
BLED = hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international 
normalized ratio, elderly, concomitant drugs/alcohol; HF = heart failure; MI = myocardial infarction; NOAC = non-
vitamin K antagonist oral anticoagulation; PAD = peripheral artery disease; TIA = transient ischemic attack.
Table 2. Baseline echocardiographic data
Characteristics Value
Total 6,275
Transthoracic echocardiography 5,253 (83.7)
LVEF (%) 61.1±11.8
<40% 201 (3.8)
≥40% 5,031 (96.2)
LA diameter (mm) 43.8±10.4
LA volume index (mL/m2) 47.5±25.9
29–33 510 (9.7)
≥34 4,225 (80.4)
E/E' 11.8±5.5
Transesophageal echocardiography 873 (13.9)
LV thrombi 13 (1.5)
Data are presented as mean±standard deviation or number (percentage).
LA = left atrium; LV = left ventricular; LVEF = left ventricular ejection fraction.
maintained in the optimal range between 2 and 3 in 33% of patients. However, the INR was 
less than 2 in 54.8% of patents.
Figure 2 shows the pattern of stroke prevention in AF and the percentage of NOAC use 
according to HAS-BLED score. Whereas warfarin was more frequently used than NOACs in 
patients with HAS-BLED score ≥4, the opposite was true in patients with HAS-BLED score 
≤3. Apixaban was used in 41.5% of patients with HAS-BLED score ≥3. Dose reduction was 
performed in accordance to the manufacturer's recommendation in 2,064 (70.0%) patients.
Pattern of and adherence to rate control therapy
Rate control was performed in 3,383 (53.9%) patients. Rate control medication was 
prescribed in 192 of 244 (85.7%) patients with LVEF <40% and in 3,191 of 3,383 (94.3%) 
patients with LVEF ≥40%.
Figure 3 shows the pattern of and adherence to rate control therapy. In patients with LVEF 
<40%, β-blockers, digoxin, and both were adequately used in 65.6%, 5.2%, and 19.3% of 
patients, respectively. However, a CCB was inadequately used in 9.9% of patients. The mean 
heart rate was 79.9±18.1 beats per minutes (bpm).
In patients with LVEF ≥40%, β-blocker, CCB, digoxin, and combination therapy were used in 
73.4%, 13.4%, 4.1%, and 9.1% patients, respectively. The mean heart rate was 75.8±16.5 bpm 
in patients with LVEF ≥40%.
Rhythm control
A rhythm control strategy was chosen in 3,414 (54.4%) of patients, including AADs and 
catheter ablation in 51.8% and 16.2%, respectively.
Figure 4 shows the pattern of and adherence to rhythm control therapy. Amiodarone was 
used in 20.4% of 3,088 patients with no or minimal signs of structural heart disease. Class Ic 
drugs were inadequately prescribed in 41.5% of 243 patients with CAD, valvular heart disease 
(VHD), or LVH. In 83 patients with HF on rhythm control medication, amiodarone and 
catheter ablation were adequately used in 69.9% and 28.9%, respectively. However, 16.9% 
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Figure 1. Anticoagulation and adherence to anticoagulation guidelines according to stroke risk: (A) number of patients and (B) percentage of patients. 
med = medicine; NOAC = non-vitamin K antagonist oral anticoagulation. 
*Patients who were non-adherent to the guidelines are marked.
were prescribed inadequate AADs, including 14.5% who took a class Ic drug, 1.2% who took 
dronedarone, and 1.2% who took sotalol.
Finally, among 3,414 patients with rhythm control medication, nonadherence to guidelines 
was observed in 765 (12.2%), including 641 (18.8%) patients with no or minimal signs of 
structural heart disease, 110 with CAD (VHD or LVH), and 14 with HF.
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DISCUSSION
This study shows how successfully guidelines can be applied in the real world. Stroke 
prevention, rate control, and rhythm control were performed in 70.1%, 53.9%, and 54.4% of 
patients, respectively. Anticoagulation was used adequately in 82.7% and 71.5% of patients 
with high and low stroke risk. However, stroke prevention for AF was inadequately performed 
in 19.2%. For rate control in patients with LVEF <40%, although β-blocker or digoxin was 
adequately used in 90.1%, a CCB was inadequately used in 9.9%. Finally, rhythm control was 
inadequately performed in 22.4% of patients.
Asian AF patients are included in several global AF registries or randomized NOAC 
trials. Among 1,063 patients enrolled in the Phase I Global Registry on Long-term Oral 
Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry, 713 
(67.1%) Chinese AF patients were included (not Korean).17) Among 15,641 patients enrolled 
in the Phase II GLORIA-AF registry, 3,071 (20.3%) Asian AF patients from China, Hong 
Kong, Russia, Singapore, South Korea, and Taiwan were included.18) In all 4 major NOAC 
trials, the proportion of Asian patients is around 10–15%.19-22) Therefore, Asian AF data is still 
insufficient. Even in Asia, the characteristics of stroke differ between countries.4)23) Moreover, 
because several types of NOACs are not allowed in Taiwan or Australia, the usage of NOACs 
cannot be universally applied for Korean AF patients. The most unique and novel feature of 
this study is the inclusion of the largest, most recent Korean AF registry, which can identify 
the clinical and treatment characteristics of Korean AF patients.
VKAs have been the mainstay of OAC treatment for several decades and reduce the relative 
risk of stroke in patients with AF by approximately 64%.24) However, compared with 
warfarin, NOAC agents have all demonstrated at least similar efficacy and safety in stroke 
prevention.19-22) With respect to stroke prevention, warfarin underuse is well recognized in 
patients with AF.25) The underuse of antithrombotic therapy and inadequate anticoagulation 
can lead not only to ischemic stroke, but also to death or severe disability.26) Using a sample 
cohort from the Korean National Health Insurance Data Sample Cohort (K-NHID-Sample 
Cohort) from 2004 through 2013, we reported that, although the mean CHA2DS2-VASc score 
increased from 3.5 to 4.4 in the AF population, the proportion of patients who received 
anticoagulation therapy with warfarin was 18.2–16.7%, showing no significant change for the 
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decade.1) In this study, OAC was adequately used in 82.7% of patients with a high stroke risk 
(CHA2DS2-VASc score ≥2). This result is consistent with the result of the GLORIA-AF registry 
phase 2,18) which reported an OAC rate of 83.2% in the same risk group. However, the usage 
rate of NOACs was higher in this study (61.4%) than in the GLORIA-AF registry phase 2 
(49.9%).
The high frequency of inadequate antithrombotic therapy in 54.6% patients with a low stroke 
risk might be explained by cardioversion and catheter ablation. However, the relatively high 
inadequate use of aspirin of 25.1% in patients with a low stroke risk should be corrected.
Other studies reported a risk-treatment paradox in which OAC decreased with increasing 
stroke risk.27) However, this study shows that the OAC rate was consistently maintained even 
in patients with a high bleeding risk. Interestingly, warfarin was more frequently used than 
NOACs in patients with a high HAS-BLED score ≥4. Dabigatran was the most common NOAC 
used in the GLORIA-AF registry phase 218) in all regions including Asia. However, in this 
study, apixaban was most commonly used.
The optimal heart rate target in patients with AF is unclear. A lenient heart rate target of 
110 bpm is an acceptable initial approach regardless of HF status, unless symptoms call for 
stricter rate control. There was no difference in the composite of clinical events (14.9% in the 
strict rate control group, 12.9% in the lenient group),28) New York Heart Association class, or 
hospitalizations.28) Consistently, according to the K-NHID-Sample Cohort, the proportion 
of patients who received rate control therapy rate decreased from 53.7% to 46.1% in 2004 
to 2013.1) In this study, rate control was performed in 53.9% of patients. The proportion 
of rate control therapy is less than that in a 2007 study on pharmacotherapy in Medicare 
beneficiaries with AF, which showed that most enrollees were on rate-control agents 
(74.0%).29)
Rate control with β-blockers or nondihydropyridine CCBs is a class I guideline 
recommendation for the management of patients with AF.14) Among patients receiving a rate 
control agent, 65.6% with LVEF <40% and 73.4% with LVEF ≥40% were taking a β-blocker. 
The proportion of CCB use was relatively low (13.4% patients with LVEF ≥40%).
In this study, 54.4% of enrollees were receiving AAD therapy, consistent with large AF 
registries, which often exceed 50%.30) Among the AADs, class Ic drugs were the most 
commonly prescribed. Because amiodarone is often considered a last-resort drug for AF, 
the preponderance of amiodarone use might be related to age and lack of response to other 
agents. Physicians might also prescribe amiodarone earlier in older patients. In this study, 
amiodarone use was greater among patients with AF and HF, consistent with guidelines.14)
Our study has several limitations. First, our analysis of medication use focused on 
prescriptions filled in the first few months of the calendar year (the first 4 months), and we 
were unable to ascertain longitudinal adherence. Second, since all patients were enrolled 
from tertiary centers, the current registry is not free from referral bias.
Medication use for AF varies according to underlying risks and comorbid diseases. In the 
recently developed Korean AF registry, the nonadherence rate was 17.2%, 9.9%, and 22.4% 
for stroke prevention, rate control, and rhythm control, respectively. This study shows how 
successfully guidelines can be applied in the real world in Korean AF patients.
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